Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders
Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Co-Chairs


George W. Sledge, Jr., MD
Ballve-Lantero Professor
of Oncology
Co-Director, Breast Cancer Program
Indiana University Cancer Center
Indianapolis, IN
Co-Chair, Breast Committee, The Eastern Oncology Cooperative Group (ECOG)

Dennis J. Slamon, MD, Ph.D.
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Johnson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, California

Organizing Committee

Julie R. Gralow, MD
Associate Professor of Medical Oncology
University of Washington School of Medicine
Cancer Care Alliance
Seattle, WA
Co-Chair, Breast Committee, The Southwest Oncology Group (SWOG)

Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Co-Chair, Breast Committee, The Cancer and Leukemia Group B (CALGB)

Mark Pegram ,MD
Professor of Medicine and Oncology
University of Miami Cancer Center
Miami, FL

Edith A. Perez, MD
Professor of Medicine
Director, Clinical Research,
Mayo Clinic
Jacksonville, FL
Chair, Breast Committee, The North Central Cancer Treatment Group (NCCTG)

Peter M. Ravdin, MD, PhD
Research Professor,
Department of Biostatistics
MD Anderson Cancer Center
Houston, TX

Eric P. Winer, MD
Director, Breast Oncology Center
Thompson Investigator in Breast Cancer Research
Department of Medical Oncology
Dana-Farber Cancer Institute /
Harvard Cancer Center
Boston, MA
Co-Chair, Breast Committee, The Cancer and Leukemia Group B (CALGB)

Additional Expert Faculty

Doctor

Sunil Badve, MD
Associate Professor of Pathology
Clarian Pathology Laboratory
Indiana University Cancer Center

Doctor

Donald A. Berry, PhD
Head, Division of Quantitative Sciences
Professor and Frank T. McGraw Memorial Chair for Cancer Research
Chairman, Department of Biostatistics
MD Anderson Cancer Center

Doctor

Powel H. Brown, MD, PhD
Professor of Medicine,
Baylor College of Medicine
Associate Director
of Cancer Prevention,
Dan L. Duncan Cancer Center
Director of Cancer Prevention and Population Sciences Program,
Dan L. Duncan Cancer Center
Associate Director of Research, Breast Center
Baylor College of Medicine

Doctor

Lisa A. Carey, MD
Medical Director, UNC Breast Center
University of North Carolina -
Lineberger Comprehensive Cancer Center

Doctor

Graham A. Colditz, MD, DrPh
Niess-Gain Professor
in the School of Medicine,
Department of Surgery,
Associate Director Prevention
and Control,
Alvin J. Siteman Cancer Center,
Washington University School of Medicine

Doctor

Armando E. Giuliano, MD
Chief of Science and Medicine
Breast and Endocrine Program
John Wayne Cancer Institute

Doctor

Richard J. Gralla, MD
President, Multinational Association of Supportive Care
in Cancer (MASCC)
Past President and Current Board Member, New York Lung Cancer Alliance
New York, NY

Doctor

David M. Loesch, MD
Private Practice
US Oncology
Indianapolis, IN

Doctor

Eleftherios P. Mamounas, MD, MPH, FACS
Professor of Surgery,
Northeastern Ohio Universities College of Medicine
Medical Director, Aultman Cancer Center,
Chairman, Breast Committee,
National Surgical Adjuvant Breast
and Bowel Project (NSABP)

Doctor

Olufunmilayo Olopade, MB, BS
Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics
Director, Hematology/Oncology
University of Chicago

Doctor

Soonmyung Paik, MD
Director, Division of Pathology National Surgical Adjuvant Breast
and Bowel Project (NSABP)

Doctor

Charles M. Perou, PhD
Associate Professor
Department of Genetics
University of North Carolina
At Chapel Hill

Doctor

Martine Piccart-Gebhart, MD, PhD
Head of the Chemotherapy Department
Jules Bordet Institute
President, European Organization for the Research and Treatment of Cancer (EORTC)

Doctor

Lori J. Pierce, MD
Vice Provost for Academic and Faculty Affairs Professor, Department of Radiation Oncology
University of Michigan

Doctor

Malcolm Pike, MD
Professor and Acting Chair, Flora L. Thornton Professor
USC Norris Cancer Center

Doctor

Kathleen I. Pritchard, MD
Chair of the Breast Cancer Site Group
Toronto-Sunnybrook Regional Cancer Center

Doctor

Lajos Pusztai, MD, DPhil
Associate Professor of Medicine
Department of Breast Medical Oncology
MD Anderson Cancer Center

Doctor

Mary Lou Smith
Co-chair,
ECOG Patient Representative Committee
Co-Founder,
Research Advocacy Network

Joseph A. Sparano, MD
Professor of Medicine,
Albert Einstein College of Medicine,
Director, Breast Evaluation Center,
Montefiore-Einstein Cancer Center

Doctor

Frank A. Vicini, MD
Chief of Oncology Service
Program Director, Radiation Oncology
William Beaumont Hospital

Doctor

Jeffrey N. Weitzel, MD
Professor of Medicine,
Medical Oncology
Director of Clinical Cancer Genetics and Cancer Screening and Prevention Program
City of Hope Comprehensive Cancer Center

 

 

Tell a friend about this symposium Print the Agenda Email the Agenda

A completely new concept in breast cancer symposia, integrating molecular diagnostics, personalized surgical and radiation techniques and chemotherapy, hormonal therapy and targeted therapeutics for improving breast cancer patient care.


CO-CHAIRS

George W. Sledge, Jr., MD
Ballve-Lantero Professor of Oncology
Co-Director, Breast Cancer Program
Indiana University Cancer Center, Indianapolis, IN
Co-Chair, Breast Committee, The Eastern Oncology Cooperative Group (ECOG)

Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, California



ORGANIZING COMMITTEE

Julie R. Gralow, MD
Associate Professor of Medicine and Medical Oncology
University of Washington School of Medicine
Cancer Care Alliance, Seattle, WA
Co-Chair, Breast Committee, The Southwest Oncology Group (SWOG)

Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Co-Chair, Breast Committee, The Cancer and Leukemia Group B (CALGB)

Mark Pegram, MD
Professor of Medicine and Oncology
University of Miami Cancer Center
Miami, FL

Edith A. Perez, MD
Professor of Medicine
Director, Clinical Research, Mayo Clinic
Jacksonville, FL
Chair, Breast Committee, The North Central Cancer Treatment Group (NCCTG)

Peter M. Ravdin, MD, PhD
Research Professor
Department of Biostatistics
MD Anderson Cancer Center
Houston, TX

Eric P. Winer, MD
Director, Breast Oncology Center
Thompson Investigator in Breast Cancer Research
Department of Medical Oncology
Dana-Farber Cancer Institute /
Harvard Cancer Center
Boston, MA
Co-Chair, Breast Committee,
The Cancer and Leukemia Group B (CALGB)



   
Educational Statement of Need
Overview
Disclosure
Target Audience
Learning Objectives
CME Credit Information
Agenda
Faculty
Educational Grant Sponsorship Opportunities
Trump Sonesta Hotel Information
Registration
   

Agenda Back to Top
January 19, 2008 - Saturday
Session 1: Introduction & Overview
CHAIRS: George Sledge and Dennis Slamon
8:00AM – 8:15AM Personalizing breast cancer therapy in the USA and Canada George Sledge and Dennis Slamon
8:15AM – 8:30AM The BIG strategy for personalizing breast cancer therapy Martine Piccart-Gebhart
8:30AM – 8:45AM The promise of personalized medicine: a breast cancer survivor's perspective Mary Lou Smith

Session 2: Personalizing Therapies for the Prevention of Breast Cancer
CHAIR: Julie Gralow

8:45AM – 9:05AM Predicting who will develop breast cancer and the influence of endocrine therapy on the risk for developing breast cancer Malcolm Pike
9:05AM – 9:25AM The role of genetics and breast cancer prevention Jeff Weitzel
9:25AM – 9:45AM Drug prevention strategies for patients at risk of developing breast cancer Powel Brown
9:45AM – 10:05AM Lifestyle and behavior modifications for prevention of breast cancer Graham Colditz
10:05 AM – 10:25AM Patients with a genetic predisposition for developing breast cancer Olufunmilayo I. Olopade
10:25AM – 10:40AM   Q & A (Interactive Panel Discussion with Faculty and Audience)
10:40AM – 10:50AM

BREAK

Session 3: Diagnosis and Molecular Classification of Breast Cancer for Personalizing Therapies 
CHAIR: Eric Winer
10:50AM – 11:10AM What are the roles of gene expression arrays as prognostic biomarkers? Charles Perou
11:10AM – 11:30AM What is the clinical role of biomarkers as predictors of drug response? Soonmyung Paik
11:30AM – 12:00PM

Q & A (Interactive Panel Discussion with Faculty and Audience)

12:00PM – 1:00PM LUNCH
1:00PM – 1:20PM Circulating tumor cells as predictive and prognostic markers Massimo Cristofanilli
1:20PM – 1:40PM The evolving role of histopathology in the era of gene arrays? Sunil Badve
1:40PM – 2:00PM Prediction of therapeutic response and prognosis: Mammaprint® and beyond Martine Piccart-Gebhart
2:00PM – 2:20PM Prediction of therapeutic response and prognosis utilizing OncotypeDX® George Sledge
2:20PM – 2:40PM  Q & A (Interactive Panel Discussion with Faculty and Audience)
2:40PM – 3:00PM BREAK
3:00PM – 3:20PM  

Anatomy still matters in the "Biologic Era"

Eric Winer
3:20PM – 3:40PM ASCO CAP Guidelines as Predictors of Response Mark Pegram
3:40PM – 4:00PM “Point-Counter-Point:”
Classical Histology versus Molecular Classification for selection of specific drug therapies? 
Sunil Badve [classical] versus Soonmyung Paik [gene expression arrays])

4:00PM –
4:20PM

Future directions and developing predictors and individualization therapy Lajos Pusztai
4:20PM – 4:40PM What are the optimal statistical aspects for biomarkers and clinical trial design? Donald Berry
4:40PM – 5:00PM  Q & A (Interactive Panel Discussion with Faculty and Audience)
January 20, 2008 – Sunday
Session 4: Personalized Approaches to Local-Regional Control of Breast Cancer
CHAIR: Lori Pierce
7:30AM – 7:50AM Personalized surgical therapy and future directions Armando Giuliano
7:50AM – 8:10AM Personalized radiation therapy and future directions Lori Pierce
8:10AM – 8:30AM Update on accelerated partial breast irradiation Frank Vicini
8:30AM – 8:50AM Individualizing loco-regional therapy with the use of neoadjuvant chemotherapy Eleftherios Mamounas
Session 5: Clinical Applications of Personalized Therapies of ER+ Breast Cancers
CHAIR: Edith Perez
8:50AM – 9:10AM Personalized approaches using SNPs (single nucleotide polymorphisms) to selecting agents for patients with metastatic ER+ breast cancer Edith Perez
9:10AM – 9:30AM Molecular predictors of response to adjuvant endocrine therapy in ER+ breast cancer Lajos Pusztai
9:30AM – 9:50AM Q & A (Panel Discussion with Faculty and Audience)
9:50AM – 10:10AM BREAK
Session 6: Clinical Applications of Personalized Therapies of HER2+ Breast Cancers
CHAIR: Dennis Slamon
10:10AM – 10:30AM The role of Topo-II and prediction of response to anthracyclines Kathleen Pritchard
10:30AM – 10:50AM Personalized approaches to selecting targeted therapies and other chemotherapies for patients with metastatic HER2+ breast cancer Dennis Slamon
10:50AM – 11:10AM Predictors of response and personalized approaches to selecting patients for adjuvant and neo-adjuvant trastuzumab therapy in HER2+ breast cancer Francisco Esteva
11:10AM – 11:30AM Clinical applications of inhibiting Heat Shock Protein-90 Clifford Hudis
11:30AM - 11:50AM “Point-Counter-Point:”
FISH versus IHC?
George Sledge versus Michael Press
11:50AM– 12:10PM  “Point-Counter-Point:”
Which therapies should be used for trastuzumab failures?
Dennis Slamon versus Clifford Hudis

12:10AM–
12:30PM

Q & A (Interactive Panel Discussion with Faculty and Audience)
12:30PM – 1:20PM LUNCH
Session 7:  Clinical Applications of Personalized Therapies of Triple-Negative Breast Cancers
CHAIR:  Lisa Carey

 

1:20PM –
1:40PM

Triple-negative breast cancer: personalized approaches to therapy of advanced disease Lisa Carey
1:40PM – 2:00PM Predictors of response and personalized approaches to selecting patients for adjuvant chemotherapy and targeted therapy in ER- breast cancer (adjuvant taxanes) Joseph Sparano
2:00PM – 2:20PM Androgen receptor positive (AR+) breast cancers? Clifford Hudis
2:20PM – 2:40PM Q & A (Panel Discussion with Faculty and Audience)
2:40PM – 3:00PM BREAK
Session 8: New Targets and Future Directions for Personalized Therapies of Breast Cancer
CHAIR: Peter Ravdin
3:00PM – 3:20PM Therapeutic individualization for anti-angiogenic therapy George Sledge
3:20PM – 3:40PM  Personalizing treatment of bone metastases, and can biomarkers predict metastatic sites? Julie Gralow
3:40PM – 4:00PM  Anti-emetics in 2008-targeting anti-emetic agents and doses for appropriate breast cancer patients Richard Gralla
4:00PM – 4:0PM

Designing optimal clinical trials: selecting and prioritizing which patients and which similar new drugs for inclusion in clinical trials

Peter Ravdin
4:20PM - 4:40PM Q & A (Panel Discussion with Faculty and Audience)
4:40PM Conclusions (George Sledge and Dennis Slamon)
Educational Grants

Sincere appreciation is extended to the following companies for their generous support of this educational meeting:
Genentech BioOncology, Novartis, Bristol-Myers Squibb, Lilly, Abraxis BioScience, AstraZeneca, Genomic Health, Eisai, sanofi-aventis, Bayer, Onyx, AviaraDx, Abbott

© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.